Table 1 Clinicopathological characteristics of the study population
Variables | GD Group | Control Group | p-value |
|---|---|---|---|
Age (years) | 46 ± 14 (16–78) | 46 ± 14 (19–75) | 0.236 |
Gender | |||
Female | 54 (82%) | 54 (82%) | 1.000 |
Male | 12 (18%) | 12 (18%) | 1.000 |
MNTS | 4.92 ± 4.6 | 8.63 ± 5.7 | *0.03 |
Bethesda Category | 2.70 ± 1.5 | 3.82 ± 1.5 | *0.04 |
Nodule status | |||
Without nodule | 15 (23%) | 17 (26%) | 0.788 |
With nodule | |||
Solitary nodule | 18 (27%) | 26 (39%) | 0.286 |
Multinodular | 33 (50%) | 23 (35%) | |
Nodule (cm) | 2.1 ± 1.3 (0.4–6.0) | 2.2 ± 1.2 (0.5–5.5) | 0.524 |
Pathology | |||
Benign | 30 (45%) | 35 (53%) | 0.385 |
If malignant | 36 (55%) | 31 (47%) | |
Incidental carcinoma | 20 (31%) | 9 (14%) | *0.04 |
Papillary carcinoma | 7 (11%) | 9 (13%) | 0.06 |
Aggressive | 9 (13%) | 13 (20%) | 0.55 |
Mean tumor size (cm) | 2.3 ± 1.3 | 1.8 ± 0.5 | *0.05 |
Lymph node metastasis | 8 (12%) | 6 (9%) | 0.599 |
Extrathyroidal extension | 4 (6%) | 5 (7.5%) | 1.00 |
Invasion | |||
Lymphatic | 4 (6%) | 0 (0%) | N/ANéA |
Vascular | 0 (0%) | 0 (0%) | N/A |
Radioactive iodine therapy | |||
Yes | 9 (14%) | 9 (14%) | 1.000 |
No | 57 (86%) | 57 (86%) | |
Recurrence | |||
Yes | 0 (0%) | 0 (0%) | 1.000 |
No | 66 (100%) | 66 (100%) | |
Survival on latest follow-up | |||
Yes | 65 (98%) | 66 (100%) | 1.000 |
No | 1 (2%) | 0 (0%) | |